This accumulation could elevate their risk of developing late-onset amyloid-related disorders, such as Alzheimer’s disease.

Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

Alzinova AB (publ) (ticker: ALZ) hereby announces that the Company's CMO is stepping down from her role after mutual agreement. The basis is a strategic decision to appoint a CMO in place at the Compa ...

IV Maintenance Dosing for the treatment of Early Alzheimer's Disease Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease ...

With the first amyloid-targeting drug now approved for Alzheimer ... and sustained” reduction in soluble APP alpha and beta (sAAPa and sAAPb) in the cerebrospinal fluid (CSF) of patients ...

Think your brain is too old to learn new tricks, let alone keep cognitive decline at bay? Think again. Research featured in the journal Cell Stem Cell in 2019 revealed that neurons continue to form in ...

The US Food and Drug Administration (FDA) has approved a new dosing regimen for LEQEMBI, a treatment for early Alzheimer’s disease, according to Eisai and Biogen Inc. The maintenance dosing will now ...

Mitochondria are crucial organelles for cellular homeostasis, regulating processes such as ATP production, reactive oxygen ...